Explorative outcomes
Tumor necrosis
DISEASE, TUMOR NECROSIS

Biomarkers:Fecal calprotectinC-reactive proteinImmunology, biomarkers (Panel - cytokines):Interleukin 6 Interleukin 8 Interleukin 10 Tumor necrosis factor alpha The outcomes regarding the quality of life are measured at baseline and week 12, whereas the disease scores and biomarkers are measured in weeks 0, 4, 8, and 12. We will analyze blood and stool samples at baseline, 4, 8, and 12 weeks. The analyses are carried out within 5–7 days after the samples are collected, except for the analysis of cytokines which are analyzed at the end of the study.